home > drugs a-z list > botox cosmetic (onabotulinumtoxina for injection) drug center > botox cosmetic (onabotulinumtoxina for injection) drug - clinical pharmacology

BOTOX® Cosmetic (onabotulinumtoxina for injection) blocks neuromuscular transmission by binding to acceptor sites on motor nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings. When injected intramuscularly at therapeutic doses, BOTOX® Cosmetic (onabotulinumtoxina for injection) produces partial chemical denervation of the muscle resulting in a localized reduction in muscle activity. In addition, the muscle may atrophy, axonal sprouting may occur, and extrajunctional acetylcholine receptors may develop. There is evidence that reinnervation of the muscle may occur, thus slowly reversing muscle denervation produced by BOTOX® Cosmetic (onabotulinumtoxina for injection) .

Pharmacokinetics

Using currently available analytical technology, it is not possible to detect BOTOX® Cosmetic (onabotulinumtoxina for injection) in the peripheral blood following intramuscular injection at the recommended doses.

Clinical Studies

Glabellar Lines

Two phase 3 randomized, multi-center, double blind, placebo-controlled studies of identical design were conducted to evaluate BOTOX® Cosmetic (onabotulinumtoxina for injection) for use in the temporary improvement of the appearance of moderate to severe glabellar facial lines. The studies enrolled healthy adults (ages 18 to 75) with glabellar lines of at least moderate severity at maximum frown. Patients were excluded if they had ptosis, deep dermal scarring, or an inability to substantially lessen glabellar lines even by physically spreading them apart. Subjects received a single treatment with BOTOX® Cosmetic (onabotulinumtoxina for injection) (N=405, combined studies) or placebo (N=132, combined studies). Injection volume was 0.1 mL/injection site, for a dose/injection site in the active treatment groups of 4 Units. Subjects were injected intramuscularly in five sites, 1 in the procerus muscle and 2 in each corrugator supercilii muscle, for a total dose in the active treatment groups of 20 Units.

The co-primary efficacy endpoints were the investigator's rating of glabellar line severity at maximum frown and the subject's global assessment of change in appearance of glabellar lines, both at Day 30 post-injection. For the investigator rating, using a 4-point grading scale (0=none, 3=severe) a responder was defined as having a severity grade of 0 or 1. For the subject's global assessment of change, the ratings were from +4 (complete improvement) to -4 (very marked worsening). A responder was defined as having a grade of at least +2 (moderate improvement). After completion of the randomized studies, subjects were offered participation in an open label, repeat treatment study to assess the safety of repeated treatment sessions.

The combined results of these two efficacy trials are presented here. The mean age was 46 years, with 32 patients (6%) ≥ 65 years of age. Most of the subjects (82%) were women, and Caucasian (84%). At baseline, 210 patients (39%) had glabellar line severity scores at rest of moderate or severe.

In these studies, the severity of glabellar lines was reduced for up to 120 days in the BOTOX® Cosmetic (onabotulinumtoxina for injection) group compared to the placebo group as measured both by investigator rating of glabellar line severity at maximum frown (Table 1), and by subject's global assessment of change in appearance of glabellar lines (Table 2).

TABLE 1 : Investigator's Assessment of Glabellar Line Severity at Maximum Frown – Responder Rates (% and Number of Subjects with Severity of None or Mild)

TABLE 2 : Subject's Assessment of Change in Appearance of Glabellar Lines – Responder Rates (% and Number of Subjects with at Least Moderate Improvement)

In the subset of patients with resting severity scores of moderate or severe, the investigator assessment of a resting severity of mild or none at day 30 was also achieved by more BOTOX® Cosmetic (onabotulinumtoxina for injection) treated patients (74%, 119/161) than placebo treated patients (20%, 10/49).

Analysis of the limited number of patients 65 years or older suggested lower treatment-associated response compared to patients less than 65 years of age. (Table 3).

TABLE 3 : Investigator's and Subject's Assessment – Responder Rates for Subjects < 65 and ≥ 65 Years of Age at Day 30

Exploratory analyses by gender suggested that responder rates in the BOTOX® Cosmetic (onabotulinumtoxina for injection) treated group were higher for women than for men for both the investigator assessment (day 30; 85% of 334 women, 59% of 71 men) and the Subject Assessment (day 30; 93% of women, 72% of men). In the limited number of non-Caucasian patients (n=64 in the BOTOX® Cosmetic (onabotulinumtoxina for injection) treated group) the responder rates were similar to those observed in the Caucasian patients.

Last reviewed on RxList: 8/12/2009
This monograph has been modified to include the generic and brand name in many instances.